{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:51:52Z","timestamp":1794019912661,"version":"4.8.0"},"reference-count":95,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Hereditary predisposition substantially shapes prevention and management across urologic oncology. This narrative review synthesizes contemporary, practice-oriented guidance on whom to test, what to test, how to act on results, and how to implement care equitably for hereditary forms of prostate cancer, renal cell carcinoma (RCC), urothelial carcinoma, pheochromocytoma\/paraganglioma (PPGL), and adrenocortical carcinoma (ACC). We delineate between forms of indication-driven germline testing (e.g., universal testing in metastatic prostate cancer; early-onset, bilateral\/multifocal, or syndromic RCC; reflex tumor mismatch repair (MMR)\/microsatellite instability (MSI) screening in upper-tract urothelial carcinoma (UTUC); universal testing in PPGL; universal TP53 testing in ACC) and pair these strategies with minimum actionable gene sets and syndrome-specific surveillance frameworks. Key points include targeted prostate-specific antigen screening in BRCA2 carriers and the impact of BRCA\/ATM variants on reclassification during active surveillance; major hereditary RCC syndromes with genotype-tailored surveillance and pathway-directed therapy (e.g., HIF-2\u03b1 inhibition for von Hippel\u2013Lindau disease); UTUC\/bladder cancer in Lynch syndrome with tumor MMR\/MSI screening, annual urinalysis (selective cytology), and immunotherapy opportunities in deficient MMR disease\/MSI-H; PPGL management emphasizing universal germline testing, intensified surveillance for SDHB, cortical-sparing adrenalectomy, and emerging HIF-2\u03b1 inhibition; and ACC care modified by Li\u2013Fraumeni syndrome (minimization of radiation\/genotoxic therapy with whole-body imaging surveillance). Testicular germ cell tumor remains largely polygenic, with no routine germline testing in typical presentations. Finally, we provide pre-\/post-test genetic-counseling checklists and mainstreamed workflows with equity metrics to operationalize precision care and close real-world access gaps.<\/jats:p>","DOI":"10.3390\/curroncol32120698","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:39:18Z","timestamp":1765442358000},"page":"698","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications"],"prefix":"10.3390","volume":"32","author":[{"given":"Takatoshi","family":"Somoto","sequence":"first","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-7361","authenticated-orcid":false,"given":"Takanobu","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Noro","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugizaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2490","authenticated-orcid":false,"given":"Naoto","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5838-114X","authenticated-orcid":false,"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Nordic Twin Study of Cancer (NorTwinCan) Collaboration. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/modpathol.2016.171","article-title":"Upper tract urothelial carcinomas: Frequency of association with mismatch repair protein loss and lynch syndrome","volume":"30","author":"Harper","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.eururo.2018.05.036","article-title":"Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology","volume":"74","author":"Loveday","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.3390\/curroncol31110511","article-title":"The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers","volume":"31","author":"Antar","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.6004\/jnccn.2023.7105","article-title":"Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers","volume":"22","author":"Shevach","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<280::AID-PROS8>3.0.CO;2-F","article-title":"No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish fam-ilies with hereditary prostate cancer","volume":"39","author":"Wilkens","year":"1999","journal-title":"Prostate"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline Mutations in HOXB13 and Prostate-Cancer Risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2013.03.007","article-title":"Germline Homeobox B13 (HOXB13) G84E Mutation and Prostate Cancer Risk in European Descendants: A Meta-analysis of 24 213 Cases and 73 631 Controls","volume":"64","author":"Shang","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/curroncol31030086","article-title":"Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer","volume":"31","author":"Kalampokis","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"MacInnis, R.J., Severi, G., Baglietto, L., Dowty, J.G., Jenkins, M.A., Southey, M.C., Hopper, J.L., and Giles, G.G. (2013). Population-Based Estimate of Prostate Cancer Risk for Carriers of the HOXB13 Missense Mutation G84E. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054727"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/JU.0000000000003492","article-title":"Early Detection of Prostate Cancer: AUA\/SUO Guideline Part II: Considerations for a Prostate Biopsy","volume":"210","author":"Wei","year":"2023","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline Mutations in ATM and BRCA1\/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fiorentino, V., Martini, M., Dell\u2019aquila, M., Musarra, T., Orticelli, E., Larocca, L.M., Rossi, E., Totaro, A., Pinto, F., and Lenci, N. (2020). Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. Diagnostics, 11.","DOI":"10.3390\/diagnostics11010010"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early Detection of Prostate Cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening","volume":"210","author":"Wei","year":"2023","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rcl.2023.06.009","article-title":"Active Surveillance for Prostate Cancer","volume":"62","author":"Englman","year":"2023","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Carll, J., Bonaddio, J., and Lawrentschuk, N. (2025). PSMA PET as a Tool for Active Surveillance of Prostate Can-cer-Where Are We at?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103580"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bardoscia, L., Sardaro, A., Quattrocchi, M., Cocuzza, P., Ciurlia, E., Furfaro, I., Gilio, M.A., Mignogna, M., Detti, B., and Ingrosso, G. (2025). The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology. J. Pers. Med., 15.","DOI":"10.3390\/jpm15080367"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_34","unstructured":"National Comprehensive Cancer Network (NCCN) (2025, December 02). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer; Version 2. Available online: https:\/\/www.nccn.org."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1002\/cncr.33679","article-title":"Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement","volume":"127","author":"Bratslavsky","year":"2021","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae Insights: Kidney Cancer, Version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Henske, E.P., Cornejo, K.M., and Wu, C.-L. (2021). Renal Cell Carcinoma in Tuberous Sclerosis Complex. Genes, 12.","DOI":"10.3390\/genes12101585"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104538","DOI":"10.1016\/j.ejmg.2022.104538","article-title":"von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance","volume":"65","author":"Binderup","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma","volume":"83","author":"Xu","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.euo.2019.11.002","article-title":"Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals","volume":"3","author":"Forde","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrurol.2015.206","article-title":"Molecular genetics and clinical features of Birt\u2013Hogg\u2013Dub\u00e9 syndrome","volume":"12","author":"Schmidt","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41431-023-01448-z","article-title":"Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome","volume":"31","author":"Lalloo","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","article-title":"Tuberous sclerosis-associated renal cell carcinoma: A clinicopathologic study of 57 separate carcinomas in 18 patients","volume":"38","author":"Guo","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/cncr.34896","article-title":"Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance","volume":"129","author":"Daniels","year":"2023","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel\u2013Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.3390\/curroncol30100670","article-title":"Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma","volume":"30","author":"Pezzicoli","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients","volume":"51","author":"Choi","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_50","unstructured":"National Comprehensive Cancer Network (NCCN) (2025, December 02). NCCN Clinical Practice Guidelines in Oncology: Genet-ic\/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric; Version 1.2025, Updated 13 June 2025. Available online: https:\/\/www.nccn.org."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00428-023-03626-2","article-title":"Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in patients older than 60 years: An opportunity to revisit urology clinical guidelines","volume":"483","author":"Pivovarcikova","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Somoto, T., Utsumi, T., Ikeda, R., Ishitsuka, N., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., Oka, R., and Endo, T. (2025). Navigating Therapeutic Landscapes in Urothelial Cancer: From Chemotherapy to Pre-cision Immuno-Oncology. Cancers, 17.","DOI":"10.3390\/cancers17203367"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update","volume":"87","author":"Birtle","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_54","first-page":"484","article-title":"European guidelines from the EHTG and ESCP for Lynch syndrome: An updated third edition of the Mallorca guidelines based on gene and gender","volume":"108","author":"Latchford","year":"2020","journal-title":"BJS"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lindner, A.K., Schachtner, G., Tulchiner, G., Thurnher, M., Untergasser, G., Obrist, P., Pipp, I., Steinkohl, F., Horninger, W., and Culig, Z. (2021). Lynch Syndrome: Its Impact on Urothelial Carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020531"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yang, Z., Song, F., and Zhong, J. (2025). Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers, 17.","DOI":"10.20944\/preprints202510.0625.v1"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Fiorentino, V., Pizzimenti, C., Franchina, M., Rossi, E.D., Tralongo, P., Carlino, A., Larocca, L.M., Martini, M., Fadda, G., and Pierconti, F. (2023). Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512489"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Jaszek, N., Bogdanowicz, A., Siwiec, J., Starownik, R., Kwa\u015bniewski, W., and Mlak, R. (2024). Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer\u2014From Early Detection to Prognosis. J. Clin. Med., 13.","DOI":"10.20944\/preprints202411.0389.v1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"Kiemeney","year":"2010","journal-title":"J. Med. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","volume":"84","author":"Seisen","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euo.2021.11.001","article-title":"Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology-Young Academic Urologists and the Global Society of Rare Genitourinary Tumors","volume":"5","author":"Lonati","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10147-018-1299-y","article-title":"Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor","volume":"23","author":"Wakai","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/iju.15218","article-title":"Laparoscopic adrenalectomy for adrenal tumors with endocrine activity: Perioperative management pathways for reduced complications and improved outcomes","volume":"30","author":"Utsumi","year":"2023","journal-title":"Int. J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e198898","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_65","first-page":"199","article-title":"Personalized Management of Pheochromocytoma and Paraganglioma","volume":"43","author":"Bechmann","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_67","first-page":"168","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: An international expert Consensus statement","volume":"20","author":"Perrier","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.currproblcancer.2024.101116","article-title":"Management of metastatic pheochromocytomas and paragangliomas: When and what","volume":"51","author":"Sukrithan","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMc2409427","article-title":"Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma","volume":"391","author":"Alkaissi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Genturis","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(15)00991-5","article-title":"Testicular germ cell tumours","volume":"387","author":"Meyts","year":"2016","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/cncr.31667","article-title":"Klinefelter syndrome in males with germ cell tumors: A report from the Children\u2019s Oncology Group","volume":"124","author":"Williams","year":"2018","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility","volume":"33","author":"Robson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/jgc4.1469","article-title":"Genetic counseling, virtual visits, and equity in the era of COVID-19 and beyond","volume":"30","author":"Uhlmann","year":"2021","journal-title":"J. Genet. Couns."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","article-title":"Next-generation sequencing in cancer diagnosis and treatment: Clinical applications and future directions","volume":"16","author":"Ghoreyshi","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_78","first-page":"68","article-title":"Demystifying the Discussion of Sequencing Panel Size in Oncology Genetic Testing","volume":"7","author":"Gomes","year":"2022","journal-title":"Eur. Med. J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bagger, F.O., Borgwardt, L., Jespersen, A.S., Hansen, A.R., Bertelsen, B., Kodama, M., and Nielsen, F.C. (2024). Whole genome sequencing in clinical practice. BMC Med. Genom., 17.","DOI":"10.1186\/s12920-024-01795-w"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2353514","DOI":"10.1001\/jamanetworkopen.2023.53514","article-title":"Cost-Effectiveness of Whole-Genome vs Whole-Exome Sequencing Among Children With Suspected Genetic Disorders","volume":"7","author":"Nurchis","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3390\/ijms13033245","article-title":"Use of the MLPA Assay in the Molecular Diagnosis of Gene Copy Number Alterations in Human Genetic Diseases","volume":"13","author":"Stuppia","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jmoldx.2017.07.004","article-title":"Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels","volume":"19","author":"Kerkhof","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_83","first-page":"448","article-title":"Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing","volume":"20","author":"Agiannitopoulos","year":"2023","journal-title":"Cancer Genom.-Proteom."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.08.011","article-title":"Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes","volume":"69","author":"Hemminki","year":"2024","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41585-022-00580-7","article-title":"Germline testing and genetic counselling in prostate cancer","volume":"19","author":"Russo","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"105705","DOI":"10.1016\/j.ebiom.2025.105705","article-title":"Germline testing for prostate cancer: Current state and opportunities for enhanced access","volume":"116","author":"Loeb","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41416-024-02890-6","article-title":"The potential clinical utility of Whole Genome Sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 Genomes Project","volume":"131","author":"Leung","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"104505","DOI":"10.1016\/j.breast.2025.104505","article-title":"Clinical genome sequencing in patients with hereditary breast and ovarian cancer: Concept, implementation and benefits","volume":"82","author":"Witt","year":"2025","journal-title":"Breast"},{"key":"ref_89","first-page":"6255","article-title":"Arguments for and against the whole-genome sequencing of newborns","volume":"15","author":"Szalai","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jmedgenet-2017-105140","article-title":"Mainstreamed genetic testing for women with ovarian cancer: First-year experience","volume":"56","author":"Rahman","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Bokkers, K., Vlaming, M., Engelhardt, E.G., Zweemer, R.P., van Oort, I.M., Kiemeney, L.A.L.M., Bleiker, E.M.A., and Ausems, M.G.E.M. (2022). The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care\u2014A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14041059"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41391-024-00925-w","article-title":"Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer","volume":"28","author":"Vlaming","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_93","first-page":"21","article-title":"Telegenetics: An Update on Availability and Use of Telemedicine in Clinical Genetics Service","volume":"41","author":"Hristovski","year":"2016","journal-title":"J. Med. Syst."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.3390\/curroncol30060408","article-title":"Progress toward Health System Readiness for Genome-Based Testing in Canada","volume":"30","author":"Husereau","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaoncol.2018.0340","article-title":"National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer","volume":"4","author":"Childers","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/698\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:17:13Z","timestamp":1765444633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":95,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["curroncol32120698"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32120698","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}